From: Hippocampal sclerosis in women with temporal lobe epilepsy: seizure and pregnancy outcomes
Variable | WWE-MO (n=34) | WWE-S (n=13) | P-value |
---|---|---|---|
Age at pregnancy mean (SD) | 25.4 (3.0) | 26.3 (3.1) | 0.92 |
Educational years >12 (n, %) | 15 (44.1%) | 4 (30.8%) | 0.82 |
Duration of epilepsy (years, median,IQR) | 9.0 (6.0–10.0) | 10.0 (7.5–14.0) | 0.26 |
Seizure freedom in the pre-conceptional years (n,%) | 1 (2.9%) | 8 (61.5%) | 0.001* |
FBTCS frequency (none) in the preconceptional year (n,%) | 22 (64.7%) | 11 (84.6%) | 0.030* |
FIAS frequency (monthly) in the preconceptional year | 15 (44.1%) | 2 (15.4%) | 0.003* |
Levetiracetam use before pregnancy (n, %) | 10 (29.4%) | 4 (30.8%) | 0.99 |
Seizure exacerbation during pregnancy (n, %) | 17 (50.0%) | 2 (15.4%) | 0.031* |
Seizure freedom during pregnancy (n, %) | 6 (17.6%) | 10 (76.9%) | <0.001* |
Seizures in the postpartum week (n, %) | 6 (17.6%) | 1 (7.7%) | 0.69 |
Polytherapy during pregnancy (n, %) | 9 (26.5%) | 6 (46.2%) | 0.37 |
Levetiracetam use during pregnancy (n, %) | 13 (38.2%) | 5 (38.4%) | 0.99 |
ASM adherence (n, %) | 21 (61.8%) | 8 (88.9%)a | 0.30 |
Induced delivery (n, %) | 9 (26.5%) | 0 (0.0%) | 0.047* |
Cesarean section (n, %) | 19 (55.9%) | 8 (61.5%) | 0.21 |